We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
Cap. Flow
-$103M
Cap. Flow %
-4.19%
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.4M
2
MRK icon
Merck
MRK
+$20M
3
WELL icon
Welltower
WELL
+$14.4M
4
CI icon
Cigna
CI
+$9.62M
5
LLY icon
Eli Lilly
LLY
+$9.59M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
VTRS icon
Viatris
VTRS
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$139M 5.65%
1,473,710
+91,704
+7% +$8.02M
AMGN icon
2
Amgen
AMGN
$209B
$134M 5.43%
704,383
+26,528
+4% +$5.07M
JNJ icon
3
Johnson & Johnson
JNJ
$617B
$126M 5.1%
897,990
-134,638
-13% -$18M
GILD icon
4
Gilead Sciences
GILD
$163B
$114M 4.62%
1,749,388
-140,458
-7% -$9.34M
PFE icon
5
Pfizer
PFE
$142B
$87.9M 3.57%
2,182,586
+583,886
+37% +$23.4M
MRK icon
6
Merck
MRK
$321B
$82.6M 3.35%
1,040,751
+267,214
+35% +$20M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$122B
$81.6M 3.31%
443,712
+17,464
+4% +$3.23M
UNH icon
8
UnitedHealth
UNH
$383B
$80.1M 3.25%
324,133
-51,241
-14% -$13.1M
BIIB icon
9
Biogen
BIIB
$30.7B
$74.3M 3.02%
314,278
-80,624
-20% -$25.4M
ILMN icon
10
Illumina
ILMN
$31B
$73.8M 3%
244,164
-25,562
-9% -$7.45M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$77.4B
$58.1M 2.36%
141,532
+5,110
+4% +$2.1M
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$50.8M 2.06%
375,705
-120,583
-24% -$15M
INCY icon
13
Incyte
INCY
$24.9B
$45.5M 1.85%
529,133
-116,309
-18% -$9.46M
MDT icon
14
Medtronic
MDT
$110B
$44.8M 1.82%
492,002
+10,637
+2% +$952K
ELV icon
15
Elevance Health
ELV
$81.6B
$40.6M 1.65%
141,358
+211
+0.1% +$61K
TMO icon
16
Thermo Fisher Scientific
TMO
$214B
$39.1M 1.59%
142,743
-49,152
-26% -$12.2M
LLY icon
17
Eli Lilly
LLY
$1.03T
$38.3M 1.56%
295,320
+78,878
+36% +$9.59M
ABT icon
18
Abbott
ABT
$183B
$36.5M 1.48%
457,048
+65,329
+17% +$4.86M
BMY icon
19
Bristol-Myers Squibb
BMY
$132B
$35.2M 1.43%
738,044
+85,078
+13% +$4.24M
AGN
20
DELISTED
Allergan plc
AGN
$28.3M 1.15%
193,263
-41,457
-18% -$6.01M
CVS icon
21
CVS Health
CVS
$134B
$27.3M 1.11%
506,364
+45,666
+10% +$2.82M
VTRS icon
22
Viatris
VTRS
$20.7B
$26.7M 1.09%
943,152
-460,576
-33% -$13.4M
NVS icon
23
Novartis
NVS
$301B
$26.6M 1.08%
308,961
-16,595
-5% -$1.33M
ZTS icon
24
Zoetis
ZTS
$31.9B
$25.9M 1.05%
257,001
+5,586
+2% +$507K
ABBV icon
25
AbbVie
ABBV
$455B
$25.8M 1.05%
320,213
-171,865
-35% -$14.1M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.

  • Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
  • Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
  • Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
  • Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
  • Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
  • Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.